Eli Lilly


Concise Prescribing Info
Acute & maintenance treatment of schizophrenia & other psychoses where +ve &/or -ve symptoms are prominent. Alleviates secondary affective symptoms commonly associated w/ schizophrenia & related disorders. Monotherapy or in combination w/ lithium or valproate for acute manic or mixed episodes in bipolar disorder, w/ or w/o psychotic features & w/ or w/o a rapid cycling course. Prevention of recurrence in patients w/ bipolar mania. Acute treatment of schizophrenia; acute manic & mixed episodes associated w/ bipolar disorder in adolescents 13-17 yr.
Dosage/Direction for Use
Schizophrenia & related disorders Initially 10 mg once daily. Acute mania associated w/ bipolar disorder 15 mg once daily as monotherapy or 10 mg once daily in combination therapy w/ lithium or valproate. Preventing recurrence in bipolar disorder Initially 10 mg once daily. May adjust subsequently w/in the range 5-20 mg/day. Increase in dose should generally occur at intervals of not <24 hr. Elderly, severe renal or moderate hepatic impairment Initially 5 mg/day. Adolescent 13-17 yr Schizophrenia & acute manic or mixed episodes associated w/ bipolar disorder Initially 2.5 mg or 5 mg once daily. Adjust dose in increments/decrements of 2.5 mg or 5 mg when necessary. Dose range: 2.5-20 mg/day.
May be taken with or without food.
Special Precautions
Discontinue use if clinical manifestation of neuroleptic malignant syndrome or the presence of unexplained high fever w/o clinical manifestation of neuroleptic malignant syndrome. Drug reduction or discontinuation if signs or symptoms of tardive dyskinesia appear. Patients w/ elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & those treated w/ potentially hepatotoxic drugs; low leukocyte &/or neutrophil counts; history of drug-induced bone marrow depression/toxicity; bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy; hypereosinophilic conditions or w/ myeloproliferative disease; prostatic hypertrophy, paralytic ileus, narrow angle glaucoma or related conditions. Hyperglycemia, diabetes, exacerbation of preexisting diabetes, ketoacidosis & diabetic coma; lipid alterations; cardiac death; cerebrovascular adverse events (eg, stroke, transient ischemic attack). History of seizures or conditions associated w/ seizures. Concomitant use w/ levodopa & dopamine agonists; w/ other centrally acting drugs including alcohol. May affect ability to drive or operate machinery. Pregnancy. Not to be used during lactation. Childn <13 yr. Elderly patients w/ dementia-related psychosis.
Adverse Reactions
Wt gain; orthostatic hypotension; somnolence; total cholesterol: fasting borderline to high; triglycerides: fasting borderline to high, increased prolactin; glucose: fasting borderline to high. Asthenia, pyrexia, fatigue; constipation, dry mouth, increased appetite; peripheral edema; arthralgia; akathisia, edema, dizziness; increased ALT/SGPT, AST/SGOT & alkaline phosphatase, total cholesterol: fasting normal to high, triglycerides: fasting normal to high; glucose: fasting normal to high, glycosuria, high γ-glutamyltransferase & uric acid; eosinophilia, leukopenia including neutropenia.
Drug Interactions
May antagonize effects of levodopa & dopamine agonists. Increased clearance by smoking, or w/ carbamazepine. Decreased clearance w/ potent CYP1A2 inhibitors, fluoxetine & fluvoxamine. Additive pharmacological effects eg, increased sedation may occur w/ ethanol. Reduced oral bioavailability w/ activated charcoal.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Zyprexa tab 10 mg
Zyprexa tab 5 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in